Tim Slattery is an associate in the Antitrust practice.
Tim’s practice focuses on antitrust matters, including private, class action, and government antitrust litigation, merger review, antitrust counseling, and government investigations. He counsels clients in a wide range of competition and antitrust matters as well as litigation matters.
Prior to joining our firm, Tim served for four years as a staff attorney in the Health Care Division of the Federal Trade Commission’s Bureau of Competition. During his time with the FTC, he investigated and litigated alleged anticompetitive conduct in the pharmaceutical and healthcare industries, addressing agency enforcement priorities such as reverse payment settlements, product hopping, exclusive dealing, and unilateral refusals to deal with rivals. Tim was a member of the FTC’s reverse payment settlement investigation and litigation teams leading to both the Supreme Court’s ground-breaking decision in FTC v. Actavis, Inc. and an FTC-record $1.3 billion settlement with Cephalon, Inc. related to blockbuster narcolepsy drug Provigil. He also conducted investigations into physician joint ventures and reviewed physicians’ clinical integration programs with an eye toward antitrust enforcement. Tim coordinated the agency’s efforts to review and analyze pharmaceutical patent settlement filings under the Medicare Modernization Act.
B.S. in Economics & BBA, Finance, summa cum laude